United Therapeutics (NASDAQ:UTHR) Director Tommy Thompson Sells 2,000 Shares

United Therapeutics Corporation (NASDAQ:UTHR) Director Tommy Thompson sold 2,000 shares of the company’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $489.42, for a total transaction of $978,840.00. Following the transaction, the director owned 8,480 shares of the company’s stock, valued at $4,150,281.60. This trade represents a 19.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

United Therapeutics Trading Down 0.4%

Shares of NASDAQ:UTHR traded down $1.71 during mid-day trading on Friday, hitting $483.35. 60,637 shares of the company traded hands, compared to its average volume of 373,193. The stock has a market cap of $21.19 billion, a P/E ratio of 17.32, a P/E/G ratio of 1.77 and a beta of 0.84. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $537.19. The stock has a 50-day moving average price of $483.09 and a two-hundred day moving average price of $451.14.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, beating the consensus estimate of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The firm had revenue of $790.20 million during the quarter, compared to the consensus estimate of $814.80 million. During the same period last year, the firm earned $6.19 EPS. The business’s quarterly revenue was up 7.4% compared to the same quarter last year. As a group, analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in UTHR. AXQ Capital LP lifted its holdings in shares of United Therapeutics by 495.4% in the 2nd quarter. AXQ Capital LP now owns 3,888 shares of the biotechnology company’s stock worth $1,117,000 after purchasing an additional 3,235 shares in the last quarter. AE Wealth Management LLC boosted its holdings in United Therapeutics by 396.3% during the 3rd quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock valued at $1,798,000 after acquiring an additional 3,424 shares during the period. Great Lakes Advisors LLC raised its holdings in United Therapeutics by 194.7% in the 3rd quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock worth $1,888,000 after purchasing an additional 2,975 shares in the last quarter. Optimize Financial Inc purchased a new position in United Therapeutics during the 3rd quarter valued at about $444,000. Finally, Simplify Asset Management Inc. bought a new stake in shares of United Therapeutics during the third quarter valued at approximately $8,351,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Key Stories Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: UBS raised its price target on UTHR from $655 to $705 and maintained a Buy rating, implying roughly 45% upside vs. the current quote — a notable analyst endorsement that could attract buyers. Benzinga
• Negative Sentiment: Multiple insiders sold sizable blocks this week, creating downward pressure risk: CEO Martine A. Rothblatt sold 9,500 shares (~$4.65M) on Mar 4 (SEC filing). Directors and execs including Ray Kurzweil (4,910 sh), Tommy G. Thompson (2,000 sh) and EVP Paul A. Mahon (8,300 sh) also sold at ~$$483–$490 per share (SEC filings). The activity was flagged in a TipRanks piece summarizing the insider cash-outs. These disposals are large enough to influence sentiment even though many insiders retain significant holdings. TipRanks Rothblatt SEC Mahon SEC Kurzweil SEC Thompson SEC Causey SEC

Analysts Set New Price Targets

Several brokerages have issued reports on UTHR. Bank of America reaffirmed a “neutral” rating on shares of United Therapeutics in a research report on Wednesday, February 25th. UBS Group boosted their target price on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research note on Thursday. Royal Bank Of Canada increased their price objective on United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. TD Cowen lifted their price target on shares of United Therapeutics from $525.00 to $575.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Finally, Oppenheimer lifted their target price on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Nine equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $539.00.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.